작성자 Maksym Misichenko · Yahoo Finance ·
AI 에이전트가 이 뉴스에 대해 생각하는 것
IBM's $10B, 5-year commitment to quantum computing is seen as a strategic move, but the timeline for practical, error-free systems is uncertain and could lead to significant cash burn. The spin-off of Anderon as a dedicated foundry is viewed as a mixed bag, with potential to accelerate error-correction work but also risks of talent retention and foundry economics favoring independent operators.
리스크: The risk of Anderon succeeding without IBM capturing the margin, leading to a race to the bottom in manufacturing economics.
기회: Becoming the 'intellectual property landlord' for quantum computing and securing domestic supply chains against China's quantum initiatives.
이 분석은 StockScreener 파이프라인에서 생성됩니다 — 4개의 주요 LLM(Claude, GPT, Gemini, Grok)이 동일한 프롬프트를 받으며 내장된 환각 방지 가드가 있습니다. 방법론 읽기 →
5월 28일 (로이터) - IBM은 목요일에 양자 컴퓨팅에 5년 동안 100억 달러 이상을 투자할 계획이라고 발표했습니다. 이는 2029년까지 복잡한 계산을 안정적이고 오류 없이 실행할 수 있는 최초의 대규모 양자 컴퓨터를 구축하는 것을 목표로 합니다.
이번 발표는 트럼프 행정부가 지난주 9개의 양자 컴퓨팅 회사에 20억 달러의 지분 투자를 결정한 데 따른 것입니다. IBM은 새로운 벤처 기업인 Anderon에 자금의 절반을 받게 되며, 이는 미국 최초의 전용 양자 칩 제조 시설이 될 것입니다.
이 움직임은 행정부의 노력의 일환으로, 새로운 기술에서 미국의 리더십을 확보하고 중국을 견제하기 위해 양자 컴퓨팅의 성장하는 중요성을 강조합니다.
최근 기술적 돌파구는 의약품 개발부터 금융 모델링 및 암호화에 이르기까지 과제를 가속화할 수 있는 잠재력에 대한 투자자들의 관심을 불러일으켰습니다.
그러나 주요 기술적 장애물이 여전히 남아 있으며, 여기에는 실용적인 사용을 제한하는 높은 오류율이 포함됩니다. Sundar Pichai CEO는 작년에 "실용적으로 유용한" 양자 컴퓨터는 5~10년 거리에 있다고 말했습니다.
IBM은 새로운 투자가 연구 개발, 자본 지출, 생태계 파트너십, 제조 확장 및 인수 합병을 포괄할 것이라고 밝혔습니다.
이 회사는 Anderon에 10억 달러를 기여할 예정이며, 이는 외부 고객에게 칩 제조 기술을 제공하고 잠재적 고객과 이미 협상 중입니다.
또한 이 회사는 Anderon에 지적 재산, 자산 및 인력을 제공하고 새로운 회사가 성장함에 따라 추가 투자자를 유치할 것을 약속했습니다.
IBM 주식은 증권 거래 전 거래에서 1.7% 상승했습니다.
IBM은 목요일에 현재까지 90개 이상의 양자 시스템을 배포했으며, 이는 다른 모든 업계 플레이어의 합계를 능가한다고 밝혔습니다.
증권 거래 위원회에 제출된 자료에 따르면 325개 이상의 Fortune 500 기업, 스타트업, 대학 및 정부 기관이 화학, 생물학 및 재료 과학 분야의 과제를 해결하기 위해 이 회사의 양자 시스템을 사용하고 있습니다.
(Anhata Rooprai와 Aditya Soni가 Bengaluru에서 보도, Leroy Leo가 편집)
4개 주요 AI 모델이 이 기사를 논의합니다
"The 2029 large-scale target remains aspirational because error-correction breakthroughs are not guaranteed by the announced funding alone."
IBM's $10B five-year quantum spend plus $1B Anderon contribution, paired with $1B Trump-era equity, aims at error-free large-scale systems by 2029. The company already leads with 90+ deployed systems and 325+ enterprise users, yet error rates still block commercial workloads in drug discovery or cryptography. Capital outlays will hit R&D, capex and M&A without clear near-term revenue, while Pichai's 5-10 year usefulness timeline implies IBM may burn cash for years. The 1.7% premarket pop prices in narrative momentum rather than earnings traction.
U.S. policy tailwinds and Anderon's open chip foundry model could compress timelines and attract paying external customers faster than IBM's standalone roadmap suggests.
"IBM's quantum leadership in deployment doesn't translate to commercial moat if error rates remain prohibitive and government funding spreads capital across nine competitors rather than consolidating it."
IBM's $10B quantum commitment looks strategically sound on surface — they've deployed 90+ systems (vs. competitors combined), have 325 enterprise customers, and now get $1B from government co-investment via Anderon. But the article buries the real problem: Pichai's own admission that 'practically useful' quantum is 5-10 years away, and IBM's 2029 target for 'large-scale' error-free systems is almost certainly marketing. The gap between deployed systems and revenue-generating applications remains massive. IBM is essentially betting $10B that they'll crack error correction before competitors, while government money flows to nine companies — diluting IBM's relative advantage.
IBM's quantum revenue contribution to earnings is likely still negligible, and this $10B spend over five years ($2B annually) competes with capex needed for their core hybrid-cloud and software businesses. If quantum doesn't deliver commercial ROI by 2032-2033, shareholders will question whether this was strategic or a prestige project dressed up as innovation.
"IBM is transitioning from a services-heavy model to a capital-intensive quantum foundry model, aiming to monetize the entire quantum ecosystem rather than just its own hardware."
IBM’s $10 billion commitment is a strategic pivot from legacy services toward high-barrier deep tech, effectively positioning Big Blue as the primary infrastructure provider for the quantum era. By spinning off 'Anderon' as a dedicated foundry, IBM is attempting to replicate the TSMC model for quantum chips, shifting from pure research to a scalable manufacturing platform. While the 1.7% premarket pop is modest, the long-term value lies in becoming the 'intellectual property landlord' for quantum computing. However, investors should be wary of the cash burn; $2 billion in government backing is a drop in the bucket compared to the capital-intensive nature of building error-corrected quantum systems, which historically suffer from massive R&D cost overruns.
The 'Anderon' spinoff could become a capital sink that dilutes IBM's core earnings, especially if quantum supremacy remains a decade away and the foundry fails to secure enough commercial volume to offset the massive depreciation of specialized manufacturing equipment.
"The 2029 target for an error-free, large-scale quantum computer is highly optimistic; meaningful value will likely come first from incremental hardware advances and quantum-as-a-service, not a binary breakthrough."
IBM's $10B, 5-year bet signals strong commitment to quantum as a long-horizon growth theme and could bolster the US ecosystem through Anderon. However, the claim of delivering a large-scale, error-free quantum computer by 2029 is highly optimistic given known hurdles: fault tolerance requires vast qubit counts and substantial overhead, and practical quantum advantage may arrive only for narrow tasks well after 2029. The piece glosses on manufacturing, talent, and supply-chain costs, and it omits the risk that government funding could be redirected or delayed. Near-term value likely rests on incremental gains, ecosystem services, and software, not a definitive hardware breakthrough by 2029.
The strongest case against my stance is that IBM, with substantial capital and government backing, could still hit a meaningful large-scale, error-corrected quantum milestone by 2029 if rapid progress accelerates; hype might understate potential near-term commercial use cases.
"Shared grants risk standardizing components that help Anderon, yet talent poaching across nine programs threatens IBM's execution more than capital helps."
Claude correctly notes dilution across nine recipients, but this underplays how shared government grants could standardize interfaces and cryo-electronics that IBM's Anderon foundry then monetizes as the default supplier. The unmentioned risk is retention: spinning off specialized talent into a separate entity while nine other funded programs compete for the same scarce PhDs may slow IBM's internal error-correction roadmap more than extra cash accelerates it.
"Anderon's independence could cannibalize IBM's quantum IP upside while saddling the parent with capex drag."
Grok's talent-retention risk is real but understated. Anderon as a separate entity could actually *accelerate* IBM's error-correction work by attracting external capital and customers willing to fund specialized teams—a classic spinoff dynamic. The risk isn't dilution; it's that Anderon succeeds *without* IBM capturing the margin. If foundry economics favor independent operators over captive supply, IBM's $10B becomes a subsidy for competitors' manufacturing, not a moat.
"IBM's quantum investment is less about commercial ROI and more about securing a government-subsidized position as a national security critical infrastructure provider."
Claude and Grok are missing the geopolitical imperative. This isn't just a tech bet; it's a defensive play to secure domestic supply chains against China's own quantum initiatives. If the U.S. government views Anderon as a critical national security asset, the 'ROI' isn't just commercial profit—it's government-subsidized survival. IBM isn't building a product; they are building a strategic utility. The risk isn't just talent retention; it's that the project becomes a permanent ward of the state.
"Anderon independence could hollow out IBM's moat by shifting manufacturing economics away from IBM, risking margin loss even as R&D spend climbs."
While Grok is right on retention risk, the bigger flaw is that Anderon as an independent foundry could erode IBM's moat by ceding manufacturing economics to outside customers. If margins compress, external partners shoulder more capex, IBM's core advantage—the integrated hardware-software stack—unravels even as R&D burns. The timeline risk remains, but the real contrarian bet is whether IBM can monetize the foundry-scale through software/services or if leading with a subsidy creates a race to the bottom.
IBM's $10B, 5-year commitment to quantum computing is seen as a strategic move, but the timeline for practical, error-free systems is uncertain and could lead to significant cash burn. The spin-off of Anderon as a dedicated foundry is viewed as a mixed bag, with potential to accelerate error-correction work but also risks of talent retention and foundry economics favoring independent operators.
Becoming the 'intellectual property landlord' for quantum computing and securing domestic supply chains against China's quantum initiatives.
The risk of Anderon succeeding without IBM capturing the margin, leading to a race to the bottom in manufacturing economics.